Definium Therapeutics, Inc. (DFTX) Stock Overview
Explore Definium Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Definium Therapeutics, Inc. (DFTX)
Key Financials
Key Financials
Market Cap
5.9B
P/E Ratio
-12.92
EPS (TTM)
N/A
ROE
-0.85%
DFTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Definium Therapeutics, Inc. (NASDAQ: DFTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Definium Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DFTX on the NASDAQ shows an RSI of 53.27, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $62.28 for the NASDAQ listing.
Key metrics behind Definium Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -12.92 and a market capitalization of 5.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DFTX on the NASDAQ.